Association of MTMR3 rs12537 at miR-181a binding site with rheumatoid arthritis and systemic lupus erythematosus risk in Egyptian patients

Mahmoud A. Senousy1, Hebatullah S. Helmy1, Nevine Fathy1, Olfat G. Shaker2 & Ghada M. Ayeldeen2

Single nucleotide polymorphisms (SNPs) in microRNA-target sites influence an individual’s risk and prognosis for autoimmune diseases. Myotubularin-related protein 3 (MTMR3), an autophagy-related gene, is a direct target of miR-181a. We investigated whether MTMR3 SNP rs12537 in the miR-181a-binding site is associated with the susceptibility and progression of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Overall, 94 patients with RA, 80 patients with SLE, and 104 healthy volunteers were recruited. Genotyping and expression analysis of circulating MTMR3 and miR-181a were performed by qPCR. The autophagic marker MAP1LC3B was measured by ELISA. The rs12537 minor homozygote (TT) genotype was a candidate risk factor of both RA and SLE. rs12537TT was associated with lower serum MTMR3 expression and higher LC3B levels than other genotypes in patients with both diseases. Serum miR-181a expression was higher in rs12537TT carriers than in other genotypes among SLE patients. Serum miR-181a and MTMR3 levels were inversely correlated in SLE but not in RA patients. rs12537TT and serum miR-181a were positively associated with disease severity in both diseases. Our results identify a novel role of rs12537 in the susceptibility and progression of RA and SLE, possibly through impacting the interaction between miR-181a and MTMR3 leading to increased autophagy.

Rheumatoid arthritis (RA) is a disabling autoimmune disease that affects a considerable percentage of the worldwide population1. RA is accompanied by constant pain, stiffness, progressive joint destruction, and deformity2–4. Systemic lupus erythematosus (SLE) is another systemic autoimmune disorder which comprises the production of multiple autoantibodies against nuclear constituents. SLE presents with a broad spectrum of clinical manifestations that result from the deposition of immune complexes in different organs, mainly the kidney, skin, and joints, causing inflammation and tissue damage5.

The exact genesis of RA and SLE remains unknown, but it is thought to occur as a consequence of the interaction of genetic, epigenetic and environmental factors, which contribute to the continuous autoimmune process6. To date, studies explaining the genesis of RA and SLE in Egypt are very limited. Hence, the identification of susceptibility genes is urgently needed.

MicroRNAs (miRNAs) are small noncoding RNAs that fine tune gene expression at the post-transcriptional level. miRNAs are implicated in almost all aspects of cellular and humoral immunity7. Previous reports have suggested that single nucleotide polymorphisms (SNPs) can create, destroy or modify the efficiency of miRNA binding to the 3′UTR of target genes and ultimately affect an individual’s risk and prognosis of several autoimmune diseases8,9.

miR-181a is implicated in haematopoiesis, T lymphocyte maturation as well as B and T cell differentiation10. miR-181a overexpression enhanced T cell signalling strength and T cell antigen receptor (TCR) sensitivity to
pared to healthy controls (36.2% vs 57.7%, respectively), and this genotype was associated with decreased RA risk.

MTMR3, a phosphatidylinositol 3-phosphate (PI3P) phosphatase, is an autophagy-related gene involved in negative regulation of autophagy initiation. Autophagy is a destructive mechanism by which cells recycle cellular proteins and cytoplasmic components to generate energy. Autophagy participates in almost every step of innate and adaptive immunity, including pathogen recognition, antigen processing and presentation, and immune cell development, survival, proliferation and function. Dysregulation of the autophagic pathway was recently linked to the pathophysiology of a variety of autoimmune diseases, in particular SLE and RA. Indeed, genetic variation in the MTMR3 gene was associated with autoimmune IgA nephropathy in lupus nephritis, which is a major disease manifestation in SLE patients.

The SNP rs12537, which maps to the MTMR3 gene in the 22q12 region, is present in the miR-181a-binding site in the 3'UTR of the MTMR3 gene and was found to be associated with gastric cancer risk. Findings of a genome-wide association study (GWAS) in the Chinese Han population connected the MTMR3 rs12537 with the susceptibility to IgA nephropathy. However, the impact of rs12537 on RA and SLE risk and severity has not yet been investigated.

Recently, many genetic reports have generally agreed on the involvement of shared genetics in autoimmune diseases. This point of view gave us the motive to investigate whether MTMR3 SNP rs12537 is associated with the susceptibility to RA and SLE in Egyptian patients. We also explored the genetic influence of this SNP on serum MTMR3 and miR-181a expression levels, along with the correlations of the investigated parameters with the clinicopathological data of the patients. Given the role of MTMR3 in autophagy, and the previous observation that knockdown of myotubulins, MTMR3 and MTMR14 was associated with increased LC3-II levels, a marker of abnormal autophagy, our aim was extended to clarify the effect of MTMR3 rs12537 on serum levels of the specific autophagic marker human microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B, referred as LC3B).

Results

Demographic, clinical and pathological characteristics of RA and SLE patients. The demographic data from patients and healthy controls are shown in Table 1. Regarding the clinicopathological data, 52.5% of RA patients had a mild/high disease activity score for 28 joints (DAS-28), with 79%, 66%, 21%, and 23.5% of patients had arthritis, deformities, subcutaneous rheumatoid nodules, and extra-articular manifestations, respectively (Table 2). Regarding SLE, 87.5% of patients had an SLE disease activity index-2k (SLEDAI-2K) score ≥6, denoting persistent active disease requiring therapy. More severe disease (SLEDAI-2K score >12) was found in 42.5% of patients. 61.2%, 47.5% and 43.7% of SLE patients had positive anti-double stranded DNA (anti-dsDNA), low complement 3 (C3) and complement 4 (C4) levels, respectively. Proteinuria was observed in 52.5% of patients. In addition, 85% of patients had nephritis of grades II–V (Table 2).

Association of rs12537 (C/T) with the risk of RA. We performed the SNP genotyping and the subjects’ case-control status was coded. Repeated analyses using the same assay yielded concordance rates of 100%. The minor allele frequency (MAF) in the controls was similar to that in Ensembl GRCh37 release 89, 2017 and genoMAF for the SNP rs12537. The rs12537 genotypes distribution in healthy controls followed the Hardy-Weinberg equilibrium (HWE) (P = 0.1).

The genotype and allele frequencies for rs12537 in both RA and SLE patients are shown in Table 3. The rs12537 major C and minor T allele frequencies did not record a significant difference between the patients and controls in both diseases (P > 0.05). The frequency of the rs12537 CT genotype was significantly lower in RA patients compared to healthy controls (36.2% vs 57.7%, respectively), and this genotype was associated with decreased RA risk in the codominant [CT vs CC, adjusted OR (95% CI) = 0.5 (0.26–0.97), P = 0.001] and the overdominant [CT vs CC + TT, adjusted OR (95% CI) = 0.39 (0.22–0.7), P = 0.001] models taking age and sex as covariates. However, the minor homozygote TT genotype was a candidate risk factor of RA when testing the recessive model [TT vs CC + CT, adjusted OR (95% CI) = 2.84 (1.37–5.9), P = 0.004].

Association of rs12537 (C/T) with the risk of SLE. The rs12537 genotype distribution in patients with SLE showed a pattern similar to that in those with RA. In the overdominant model, CT heterozygosity was a protective risk factor against SLE [CT vs CC + TT, crude OR (95% CI) = 0.44 (0.24–0.8), P = 0.006]. However, there was no statistical significance when adjusting for age and sex (P = 0.063). Testing the recessive model revealed

| Parameter       | Healthy controls (n = 104) | RA (n = 94) | SLE (n = 80) | P value |
|-----------------|---------------------------|-------------|-------------|---------|
| Sex             | Male, n (%)               | Female, n (%)| Age (years) | Range |
|                 | 16 (15%)                  | 88 (85%)    | 36.4 ± 7.02 | (19–47) |

Table 1. Demographic data of RA, SLE patients and healthy controls. Significance difference from RA.
that the minor homozygote TT genotype was a candidate risk factor for SLE [TT vs CC + CT, adjusted OR (95% CI) = 2.29 (1.05–4.99), \( P = 0.034 \)] taking age and sex as covariates.

### Association of rs12537 with serum MTMR3 and miR-181a expression levels in RA patients.

To explore the impact of rs12537 on MTMR3 mRNA and miR-181a expression, we assessed serum MTMR3 mRNA and miR-181a expression levels in RA patients with different rs12537 genotypes. We found a significantly lower expression levels of serum MTMR3 in patients with the TT genotype than those with the CC (\( P = 0.004 \)) or CC + CT (\( P = 0.024 \)) genotype. TT genotype carriers also demonstrated lower MTMR3 expression than CT carriers with no statistical difference (\( P = 0.09 \)). MTMR3 expression levels did not differ also in the CT vs CC comparison (\( P = 0.18 \)) (Fig. 1A). Regarding miR-181a, we failed to record a significant difference in serum miR-181a expression levels among patients with different genotypes in the RA group (\( P > 0.05 \)) (Fig. 1B).

### Association of rs12537 with serum MTMR3 and miR-181a expression levels in SLE patients.

We further examined the influence of rs12537 on MTMR3 mRNA and miR-181a expression in SLE patients. We found a significantly lower expression levels of serum MTMR3 in the TT genotype carriers than in those having the CC (\( P = 0.028 \)) or CC + CT (\( P = 0.04 \)) genotype. Subjects carrying the TT genotype also demonstrated lower MTMR3 expression than CT genotype carriers with no statistical significance (\( P = 0.09 \)). MTMR3 expression levels did not differ also in the CT vs CC comparison (\( P = 0.18 \)) (Fig. 1C). Notably, serum miR-181a expression levels were overexpressed in TT genotype carriers compared to those in carriers of the CT (\( P = 0.004 \)), CC + CT

| RA Parameter | RA patients (n = 94) | SLE Parameter | SLE patients (n = 80) |
|--------------|---------------------|--------------|----------------------|
| Disease duration (y) | 6.24 ± 4.49 | ESR (mm) | 43.5 ± 30.17 |
| MS (min) | 27.23 ± 25.98 | Proteinuria (g/day) | 1.36 ± 1.5 |
| ESR (mm) | 39.64 ± 22.25 | >0.5 g/day | 42 (52.5) |
| RF, n (%) | <0.5 g/day | <0.5 g/day | 38 (47.5) |
| Positive | 68 (72) | SLEDAI-2K score | 11.35 ± 5.4 |
| Negative | 26 (28) | >12 | 34 (42.5) |
| ANA, n (%) | <12 | | 46 (57.5) |
| Positive | 12 (13) | Positive anti-dsDNA, n (%) | 49 (61.2) |
| Negative | 82 (87) | Positive | 49 (61.2) |
| DAS-28 (CRP) | 2.95 ± 1.68 | Negative | 31 (38.8) |
| Remission <2.6 | 46 (49) | Low C3, n (%) | 35 (43.7) |
| Low disease activity <3.2 | 8 (8.5) | Yes | 38 (47.5) |
| Mild disease activity 3.2–5.1 | 30 (32) | No | 42 (52.5) |
| High disease activity >5.1 | 10 (10.5) | Low C4, n (%) | 35 (43.7) |
| VAS (mm) | 5.44 ± 3.36 | Yes | 45 (56.3) |
| Swollen joint count (SJC) | 5.43 ± 5.53 | No | 45 (56.3) |
| Tender joint count (TJC) | 5.15 ± 5.37 | Arthritis, n (%) | 36 (45) |
| Arthritis, n (%) | Yes | | 48 (60) |
| Yes | 74 (79) | No | 32 (40) |
| No | 20 (21) | Mucosal ulcers, n (%) | 44 (55) |
| Deformities, n (%) | Yes | | 36 (45) |
| Yes | 62 (66) | No | 40 (50) |
| No | 32 (34) | New rash, n (%) | 40 (50) |
| Fever, n (%) | Yes | | 40 (50) |
| Yes | 14 (15) | No | 40 (50) |
| No | 80 (85) | Neurological manifestations, n (%) | 40 (50) |
| Rheumatoid nodules, n (%) | Yes | | 18 (22.5) |
| Yes | 20 (21) | No | 62 (77.5) |
| No | 74 (79) | Nephritis, n (%) | 62 (77.5) |
| Extra-articular manifestations, n (%) | Absent | | 18 (22.5) |
| Yes | 22 (23.5) | Class II–III | 34 (42.5) |
| No | 72 (76.5) | Class IV–V | 34 (42.5) |

Table 2. Clinicopathological data of RA and SLE patients. Values are expressed as mean ± SD or number (percentage). Anti-dsDNA, anti-double stranded DNA; ANA, anti-nuclear antibody; C3, complement 3; C4, complement 4; CRP, C-reactive protein; DAS-28, disease activity score-28; ESR, erythrocyte sedimentation rate; MS, muscle stiffness; RA, rheumatoid arthritis; RF, rheumatoid factor; SLE, systemic lupus erythematosus, SLEDAI-2K, SLE disease activity index-2K; VAS, visual analog scale.
| Genotype and allele | Controls n = 104 (n (%)) | RA n = 94 (n (%)) | Crude OR (95% CI) | P | Adjusted OR (95% CI) | P* | Crude OR (95% CI) | P | Adjusted OR (95% CI) | P |
|---------------------|-------------------------|------------------|------------------|---|---------------------|---|------------------|---|---------------------|---|
| **MTMR3 rs12537 C/T** |                        |                  |                  |   |                     |   |                  |   |                     |   |
| Codominant          |                        |                  |                  |   |                     |   |                  |   |                     |   |
| CC                  | 30 (28.9)               | 32 (34)          | 1.00             |   |                     |   | 26 (32.5)        | 1.00 |                     |   |
| CT                  | 60 (57.7)               | 34 (36.2)        | 0.53 (0.28–1.02) | 0.06 |                      |   | 30 (37.5)        | 0.58 (0.29–1.14) | 0.12 |                      |   |
| TT                  | 14 (13.5)               | 26 (29.8)        | 1.87 (0.83–4.22) | 0.15 | 1.89 (0.82–4.32)    | 0.13 | 24 (30)          | 1.98 (0.85–4.59) | 0.14 | 1.87 (0.77–4.49)    | 0.16 |
| **Dominant**        |                        |                  |                  |   |                     |   |                  |   |                     |   |
| CC                  | 30 (28.9)               | 32 (34)          | 1.00             |   |                     |   | 26 (32.5)        | 1.00 |                     |   |
| CT + TT             | 74 (71.2)               | 62 (66)          | 0.79 (0.43–1.43) | 0.43 |                      |   | 54 (67.5)        | 0.84 (0.45–1.58) | 0.59 |                      |   |
| **Recessive**       |                        |                  |                  |   |                     |   |                  |   |                     |   |
| CC + CT             | 90 (86.5)               | 66 (70.2)        | 1.00             |   |                     |   | 56 (70)          | 1.00 |                     |   |
| TT                  | 14 (13.5)               | 26 (29.8)        | 2.73 (1.33–5.58) | 0.005 | 2.84 (1.37–5.9)     | 0.004 | 24 (30)          | 2.76 (1.32–4.77) | 0.006 | 2.29 (1.05–4.99)    | 0.034 |
| **Overdominant**    |                        |                  |                  |   |                     |   |                  |   |                     |   |
| CC + TT             | 44 (86.5)               | 60 (63.8)        | 1.00             |   |                     |   | 50 (62.5)        | 1.00 |                     |   |
| CT                  | 60 (57.5)               | 34 (36.2)        | 0.42 (0.23–0.74) | 0.002 | 0.39 (0.22–0.7)     | 0.001 | 30 (37.5)        | 0.44 (0.24–0.8)  | 0.006 | 0.55 (0.29–1.03)    | 0.063 |
| Log-additive        |                        |                  |                  |   |                     |   |                  |   |                     |   |
| C                   | 120 (0.58)              | 98 (0.52)        | 1.00             |   |                     |   | 82 (0.51)        | 1.00 |                     |   |
| T                   | 88 (0.42)               | 90 (0.48)        | 1.25 (0.84–1.86) | 0.31 |                     |   | 78 (0.49)        | 1.3 (0.86–1.96)  | 0.24 |                     |   |

Table 3. Genotype and allele frequencies of MTMR3 rs12537 C/T in RA, SLE and healthy controls. Values are expressed as number (percentage). P* adjusted for age and sex in a logistic regression model. P values in bold are statistically significant (P < 0.05).

(P = 0.028) and CC genotypes; however, the difference for the CC genotype was not significant (P = 0.15). Serum miR-181a expression levels did not record a significant change between CT and CC genotype carriers (P = 0.5) (Fig. 1D).

**Correlation of serum miR-181a with MTMR3 levels in RA and SLE patients.** Serum miR-181a and MTMR3 expression levels were negatively correlated in SLE patients (Pearson r = -0.3, P = 0.036); yet, such correlation was not observed in RA patients.

**Correlation of rs12537 genotypes, serum miR-181a and MTMR3 levels with clinicopathological data in RA patients.** In the present study, the prognostic role that might be played by rs12537 SNP, serum MTMR3 and miR-181a expression in RA was examined (Table 4). A positive association of rs12537 with the presence of rheumatoid nodules was observed in the recessive model [TT vs CC + CT, adjusted OR (95% CI) = 3.38 (1.17–9.79), P = 0.024]. There was a positive correlation between serum miR-181a and the presence of rheumatoid factor (RF) (r = 0.23, P = 0.028). However, no correlations were found between serum MTMR3 mRNA expression and clinicopathological data among RA patients.

**Correlation of rs12537 genotypes, miR-181a and MTMR3 levels with clinicopathological data in SLE patients.** We also evaluated the prognostic role of the rs12537 SNP, serum MTMR3 and miR-181a expression levels in SLE patients (Table 5). rs12537 was positively associated with disease severity (SLEDAI-2K > 12) [TT vs CC + CT, adjusted OR (95% CI) = 3.04 (1.1–8.42), P = 0.03] and with the presence of low C4 levels [TT vs CC + CT, adjusted OR (95% CI) = 3 (1.1–8.03), P = 0.044] in the recessive model. There were significant positive correlations for serum miR-181a expression with SLEDAI-2K scores (Pearson r = 0.318, P = 0.04) and with the presence of low C4 levels (r = 0.24, P = 0.023). Interestingly, serum MTMR3 expression was negatively correlated with the presence of reduced C3 (r = -0.22, P = 0.044) and C4 (r = -0.25, P = 0.022) levels. We also recorded a negative correlation between serum MTMR3 expression and urinary protein levels (r = -0.307, P = 0.015).

**Effect of rs12537 on serum MAP1LC3B (LC3B) in RA and SLE patients.** In both diseases, we found significantly higher levels of the autophagosomal marker LC3B in sera of patients carrying the TT genotype compared to those carrying the CC or CC + CT genotypes (P < 0.05). Serum LC3B was also significantly higher in the CT genotype carriers than the CC genotype carriers among RA patients (P < 0.001), but not among SLE patients (P = 0.54). There were no significant differences in the CT vs TT comparison in both diseases (P > 0.05) (Fig. 2).
Discussion

RA and SLE are systemic autoimmune diseases; thus, they may share the same disease mechanisms and susceptibility loci. To our knowledge, we are the first to demonstrate the effects of the MTMR3 rs12537 SNP within the miR-181a-binding site on RA and SLE susceptibility and prognosis. We found that the presence of 2 T risk alleles of rs12537 in the miR-181a-binding site in the 3′ UTR of MTMR3 was a candidate for increased risk and severity of both RA and SLE among Egyptian patients recruited in this study, indicating a novel role of this SNP in the genesis and progression of both diseases. These results may partially elucidate the unexplained heritability of these autoimmune diseases. Furthermore, we found that rs12537 TT homozygosity was associated with the lowest expression levels of MTMR3 mRNA among RA and SLE patients which superimposed the highest levels of the autophagy marker, LC3B, linking MTMR3 to the deregulated autophagy in RA and SLE. Notably, the rs12537 SNP was associated with decreased MTMR3 levels and increased gastric cancer risk due to creation of a new miR-181a-binding site16. Together, these results confirm the role of this SNP in regulating MTMR3 expression. Additionally, our results suggest that rs12537 could increase the risk and progression of RA and SLE by reducing MTMR3 levels leading to increased autophagy level (Fig. 3).

MTMR3 is a member of the myotubularin-related protein family, which dephosphorylates PI3P; the synthesis of PI3P is required for autophagy initiation and regulation of autophagosome size18,24. MTMR3 negatively regulates constitutive autophagy through modulating local PI3P levels23. Indeed, targeting the myotubularin family with small inhibitor RNA (siRNA) screen revealed that knockdown of MTMR3 and MTMR14 was associated with altered autophagy markers, including LC3-II23. MTMR3 was also reported to modulate pattern recognition receptor (PRR)-induced outcomes and cytokine secretion in inflammatory bowel disease (IBD)25. MTMR3 decreased PRR-induced PI3P and autophagy levels in monocyte-derived macrophages, thereby increasing PRR-induced caspase-1 activation, autocrine IL-1β secretion, NF-κB signalling, and, ultimately, overall cytokine secretion25. Furthermore, macrophages from MTMR3 rs713875 carriers at risk of IBD exhibited increased MTMR3 expression, with subsequent increased cytokine secretion25. Moreover, genetic variants at 22q12 were associated with early-onset IBD in a GWAS, and MTMR3 expression was demonstrated to be significantly reduced in colonic biopsies from ulcerative colitis patients26. MTMR3 rs12537 was also associated with the susceptibility to IgA nephropathy; the rs12537 T allele was associated with severe proteinuria22. Together, these reports strongly implicate MTMR3 in several pathophysiological mechanisms associated with autoimmune and inflammatory disorders. Nevertheless, the exact function of MTMR3 in RA and SLE remains elusive. The MTMR3 rs9983 high-risk allele at 22q12 showed associations with lupus nephritis, with lower MTMR3 transcription levels were recorded in blood samples with the rs9983 high-risk allele and in renal biopsies from lupus nephritis and IgA nephropathy patients26. This finding is consistent with our observation that the rs12537 high-risk allele was associated with SLE.
### Table 4. Correlation of MTMR3 rs12537, serum miR-181a and MTMR3 expression levels with clinicopathological data of RA patients

| Parameter | MTMR3 rs12537 recessive model | MTMR3 rs12537 overdominant model | Serum miR-181a | Serum MTMR3 |
|-----------|-------------------------------|----------------------------------|----------------|-------------|
|           | TT (n = 28) | CC + CT (n = 66) | P<sup>a</sup> | CT (n = 34) | CC + TT (n = 60) | P<sup>a</sup> | r | P | r | P |
| Disease activity (DAS-28-CRP), n (%) | | | 0.38 | | 0.13 | 0.073 | 0.62 | --0.043 | 0.78 |
| Moderate-high (DAS-28 >3.2) | 10 (25) | 30 (75) | | 18 (45) | 22 (55) | | | | |
| Remission-low (DAS-28 <3.2) | 18 (33) | 36 (67) | | 16 (29.6) | 38 (70.4) | | | | |
| RF, n (%) | | 0.37 | | 0.58 | 0.23 | 0.028 | 0.09 | 0.55 |
| Positive | 22 (32) | 46 (68) | | 24 (35) | 44 (65) | | | | |
| Negative | 6 (23) | 20 (77) | | 10 (38) | 16 (62) | | | | |
| ANA, n (%) | | 0.99 | | --0.023 | 0.88 | --0.013 | 0.93 |
| Positive | 4 (33) | 8 (67) | | 4 (33) | 8 (67) | | 0.73 |
| Negative | 24 (29) | 58 (71) | | 30 (36.5) | 52 (63.5) | | | | |
| Arthritis, n (%) | | 0.22 | | 0.51 | --0.073 | 0.63 | 0.153 | 0.23 |
| Yes | 20 (27) | 54 (73) | | 28 (38) | 46 (62) | | | | |
| No | 8 (40) | 12 (60) | | 6 (30) | 14 (70) | | | | |
| Deformities, n (%) | | 0.24 | | 0.71 | --0.1 | 0.53 | 0.12 | 0.43 |
| Yes | 16 (26) | 46 (74) | | 24 (39) | 38 (61) | | | | |
| No | 12 (37.5) | 20 (62.5) | | 10 (31) | 22 (69) | | | | |
| Rheumatoid nodules, n (%) | 0.024 | | | 0.058 | 0.038 | 0.8 | 0.026 | 0.86 |
| Yes | 10 (50) | 10 (50) | | 4 (20) | 16 (80) | | | | |
| No | 18 (24.3) | 56 (75.7) | | 30 (41) | 44 (59) | | | | |
| Extra-articular manifestations, n (%) | 0.17 | | | 0.94 | --0.031 | 0.84 | --0.064 | 0.67 |
| Yes | 4 (18) | 18 (82) | | 8 (36) | 14 (64) | | | | |
| No | 24 (33) | 48 (66) | | 26 (36) | 46 (64) | | | | |

---

risk and reduced MTMR3 levels, along with elevated LC3B levels. This could be clarified by the fact that increased autophagic flux was noticed in T lymphocytes from lupus-prone mice as well as SLE patients. In particular, strong in CD4<sup>+</sup> T cells. In SLE, proliferating, autoreactive naïve CD4<sup>+</sup> T cells were shown to undergo enhanced autophagy to supply their metabolic needs. In addition, autophagy activation was also required for survival of autoreactive human and murine lupus B cells and for plasmablast differentiation in SLE. However, to date, the precise role of MTMR3 and its polymorphisms in RA remains unclear. Herein, we demonstrated that the presence of one or two rs12537 risk T alleles (CT or TT) was associated with markedly higher LC3B level than the 2C alleles in RA patients. These results coincided with reduced MTMR3 levels in RA patients carrying the rs12537 TT genotype compared to those carrying the CC or CT genotype, which paralleled the low MTMR3 expression in this subgroup compared to that in CC or CC + CT genotype carriers. The explanation could be based on that functional assays previously revealed that the replacement of the C allele by the T allele of rs12537 created an additional binding site (at 1653–1673) for the miR-181a in the 3′UTR of MTMR3, with perfect complementarity, inducing increased mRNA degradation. Intriguingly, we found that miR-181a was overexpressed in SLE patients carrying the TT genotype compared to those carrying the CT or CC + CT genotype, which paralleled the low MTMR3 expression in this subgroup compared to that in CC or CC + CT genotype carriers. The explanation could be based on that functional assays previously revealed that the replacement of the C allele by the T allele of rs12537 created an additional binding site (at 1653–1673) for the miR-181a in the 3′UTR of MTMR3, with perfect complementarity, inducing increased mRNA degradation. Nevertheless, we failed to record either a significant difference in miR-181a expression levels between RA patients with different rs12537 genotypes or a correlation between serum miR-181a and MTMR3 expression in the RA group, suggesting that a more complex mechanism regulates MTMR3 in RA. Indeed, only overexpression of miR-181a significantly reduced MTMR3, whereas knockdown of endogenous miR-181a did not elevate MTMR3 mRNA and protein levels in gastric cancer cell lines, arguing that MTMR3 may be deregulated by other factors in addition to miR-181a<sup>16</sup>,<sup>17</sup>. The present study further explored the role of rs12537, serum MTMR3 and miR-181a in SLE and RA prognosis. rs12537 TT genotype and higher levels of miR-181a were recorded in SLE patients with high SLEDAI-2K scores or low complement levels. We also reported a prevalence of rs12537 TT genotype and high serum miR-181a levels in RA patients with rheumatoid nodules and positive RF, respectively. Interestingly, lower serum MTMR3 expression was observed in SLE patients with severe proteinuria or low complement levels. These
findings highlight a novel role of rs12537 in the severity and progression of RA and SLE, possibly by reducing MTMR3 through increased miR-181a binding.

Notably, the present data are in accordance with recent studies that demonstrated an association between miR-181a and disease progression in SLE patients. Serum miR-181a was highly upregulated in severe SLE cases and showed correlations with anti-dsDNA as well as reduced complement levels. In fact, miR-181a is crucial in T lymphocyte maturation and function, and acts as an intrinsic antigen during T cell development. Overexpression of miR-181a increased the stimulation threshold of the TCR in mature lymphocytes and was linked to increased risk of autoimmune diseases. miR-181a also affects T cell function by targeting phosphatases, such as PTPN22 which negatively regulate T lymphocyte activation. Indeed, PTPN22 inhibition was implicated in the development and progression of RA. Speculating that miR-181a could enhance autophagy level in T cells by inhibiting MTMR3 may give an additional explanation for the involvement of this miRNA in autoimmune diseases, but this notion should be further investigated.

Table 5. Correlation of MTMR3 rs12537, serum miR-181a and MTMR3 expression levels with clinicopathological data of SLE patients. Values are expressed as number (percentage). $P$ adjusted for age and sex in a logistic regression model. $P$ values in bold are statistically significant ($P < 0.05$). Correlation was conducted by Spearman correlation. $^*$Pearson correlation.

![Figure 2. Serum MAP1LC3B (LC3B) levels in RA and SLE patients with different rs12537 genotypes. (A) RA, CC = 32, CT = 34, TT = 28, (B) SLE, CC = 26, CT = 30, TT = 24. Data are expressed as mean ± SEM.](image-url)
associated with susceptibility to RA $^{32,33}$ and SLE $^{34}$. Herein, we chose MTMR3 rs12537 and demonstrated that rs12537 can predispose to SLE and RA, probably by impacting the interaction between miR-181a and MTMR3 leading to increased autophagy.

While many studies have demonstrated associations of genetic variants related to miRNA genes or their target genes with the risk of RA or SLE $^{35–37}$, our study has several improvements on previous studies in that it is the first to propose MTMR3 rs12537 in the miR-181a-binding site as a novel genetic marker of both RA and SLE risk and prognosis. Our results also shed more light on the shared genetic factors that predispose to these two rheumatic diseases. This confirms that despite the presence of disease-specific gene sets, immune cell types, and organs that drive the distinct phenotypes of both diseases $^{38}$, some features may have a common genetic background. Our study also introduces MTMR3 as a novel biomarker of SLE progression; intensifying the notion that autophagy is linked to the pathogenesis of autoimmune diseases. Additionally, our findings demonstrated that MTMR3 deregulation could be a new mechanism by which miR-181a can regulate immune responses.

Our study has the following limitations. Being a hospital-based study, selection bias was inevitable. Our study was limited to Egyptian patients; this might limit the generalizability of our results; however, homogeneity of the population could be considered a point of strength because it reduces genetic variability. The sample size is relatively small; thus, our results should be cautiously interpreted. Additional large-scale population studies are required to reproduce our findings. Future studies should also take into account the SNP-environment interactions. Nevertheless, we believe that our findings are potentially sound for clinical personalized medicine and have potential implications in genetic counselling, diagnosis and prognosis of RA and SLE. Our findings may also open a new avenue for advanced therapeutic strategies for RA and SLE through targeting MTMR3 and autophagy.

**Conclusions**

We are the first to document that the MTMR3 rs12537 TT genotype at the miR-181a-binding site could be employed as a useful genetic marker for higher risk and poor prognosis of RA and SLE. Additionally, miR-181a and its target gene MTMR3 might be involved in SLE progression.

**Subjects and Methods**

This case-control study included 94 RA and 80 SLE cases, along with 104 healthy volunteers who were age- and gender-matched. RA and SLE patients were recruited from the rheumatology unit of Kasr Al-Ainy Hospital in Cairo, Egypt, and fulfilled the American College of Rheumatology (ACR 1987) diagnostic criteria. Full patient histories were gathered, and clinical examinations were performed on the patients. The patients were newly diagnosed and treatment-naive. Exclusion criteria included patients who were below 18 years or who had other autoimmune diseases or malignancy, or who were receiving treatment.

Disease activity in RA patients was assessed by DAS-28/C-reactive protein (CRP) as previously described $^{39}$. Clinical evaluation of SLE disease activity was conducted using the SLEDAI-2K scoring system with 24 descriptor points during 2 visits $^{40}$. SLEDAI-2K scores $\geq 6$ were used to define persistent active disease, while SLEDAI-2K scores $>12$ were used to define severe disease. Proteinuria was defined as urinary protein levels $>0.5$ g/24 hr.

We used a questionnaire, to confirm that the healthy volunteers had no history of immunological diseases and were free from other inflammatory or infectious conditions or not being treated for arthralgia, heart failure, renal failure, or autoimmune disease; at the time of recruitment. We obtained a written informed consent from all patients and controls. The study protocol conformed to the ethical guidelines of the Helsinki Declaration and was approved by the ethics committee of the Faculty of Pharmacy, Cairo University.

**Laboratory investigations.** Blood samples were collected from all participants. The patients were subjected to routine laboratory investigations, including complete blood count and erythrocyte sedimentation rate
DNA extraction and genotyping. Genomic DNA was extracted from whole blood samples in EDTA from all subjects using the QIAamp DNA MiniKit (Qiagen, Valencia, CA) according to the manufacturer’s instructions. The yield was measured by a NanoDrop 2000 (Thermo Fisher Scientific, USA). Genotyping was conducted using real-time PCR with the TaqMan allelic discrimination assay using pre-designed primer/probe sets for rs12537 (C/T) [C_2615519_1_] (Applied Biosystems, USA) as previously described. Briefly, DNA amplification was performed in a 25 μl volume using a Rotor Gene Q System (Qiagen, Valencia, CA) with the following conditions: 95 °C for 10 min, followed by 45 cycles at 92 °C for 15 s and 60 °C for 90 s.

Serum miR-181a and MTMR3 assays by RT-qPCR. Total RNA was extracted from serum by a miRNeasy extraction kit (Qiagen, Valencia, CA) and a QIAzol lysis reagent according to the manufacturer’s instructions. The quality of RNA was tested using a NanoDrop 2000 (Thermo Fisher, USA).

For miRNA, reverse transcription (RT) was performed on 100 ng of total RNA in a 20 μl RT reaction using a miScript II RT Kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions. Serum expression levels of the mature miRNA, hsa-miR-181a-5p, were evaluated using a miScript miRNA PCR primer assay and a miScript SYBR green PCR kit (Qiagen, Valencia, CA) according to the manufacturer’s protocols. The housekeeping miRNA SNORD68 was used as the internal control. Real-time PCR was performed in 20 μl reaction mixtures using Rotor Gene Q System (Qiagen) with the following conditions: 95 °C for 30 min, followed by 40 cycles at 94 °C for 15 s, 55 °C for 30 s, and 70 °C for 30 s.

For MTMR3 mRNA, RT was conducted on 100 ng of total RNA in a 20 μl RT reaction using High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, USA) according to the manufacturer’s instructions. Serum MTMR3 expression levels were evaluated using GAPDH as an internal control with customized primers and a Maxima SYBR Green PCR kit (Thermo, USA) according to the manufacturer’s protocol. The primer sequences were as follows: MTMR3-forward 5′-ACAGAGATGGGCTCAGTGTT-3′, MTMR3-reverse 5′-ACGTGCCAGT TT TGGT-CCTC-3′, GAPDH-forward 5′-CCCTTCATTGACCTCAACTA-3′ and GAPDH-reverse, 5′-TGAAGATGGTGATGGGATT-3′. Real-time PCR was performed in 20 μl reaction mixtures using Rotor Gene Q System (Qiagen) with the following conditions: 95 °C for 10 min, followed by 40 cycles at 95 °C for 15 s and 60 °C for 60 s.

The cycle threshold (Ct) is the number of cycles required for the fluorescent signal to cross the threshold in real-time PCR. miR-181a and MTMR3 mRNA expression relative to the corresponding internal control was calculated using 2−ΔΔCt, where ΔCt = Ct gene-Ct internal control.

Serum LC3 assay. Serum MAP1LC3B (LC3B) was measured by commercially available ELISA kit provided byCUSABIO Biotech Co, Ltd, Wuhan, China (Catalog #CSB-EL013403HU).

Statistical analysis. Statistical analyses for demographic, clinical and gene expression data were carried out using GraphPad Prism-5.0 (GraphPad Software, CA) and the computer program Statistical Package for the Social Science (SPSS, Chicago, IL) software version-15 for Microsoft Windows. Values were expressed as number (percentage), mean ± standard deviation (SD), or mean ± standard error of the mean (SEM) when appropriate. Continuous variables were compared using Student’s t-test or one-way ANOVA followed by Tukey’s multiple comparison test when appropriate. Categorical data were compared by the X2 test. Correlations were determined by Spearman or Pearson correlation when appropriate. For SNP analysis, crude allele and genotype frequencies were calculated and the HWE test was performed for the genotype distribution among controls and cases using the X2 test with one degree of freedom. To test the association of rs12537 with the risk of RA and SLE, unconditional multivariate logistic regression models were used to calculate the odds ratio (OR), 95% confidence interval (CI), and corresponding P-value of codominant, dominant, recessive and log-additive models, controlling for age and sex as confounders using SNPSStats online software (Institut Català d’Oncologia, Barcelona, Spain; https://www.snpstats.net/start.htm) which used the maximum likelihood ratio test. In all analyses, the major allele or the common homozygote genotype in the control population was defined as the reference category. Association of the SNP with clinicopathological data was also conducted using logistic regression models controlling for age and sex using SNPSStats. In all analyses, P < 0.05 was considered significant, with a 95% CI.

Data Availability
All data generated or analyzed during this study are included in this article.

References
1. Ogendik, M. Rheumatoid arthritis is an autoimmune disease caused by periodontal pathogens. International Journal of General Medicine 6, 383–386, https://doi.org/10.2147/ijgm.s45929 (2013).
2. Gamal, R. M., Mahrain, S. A., Abo El Fetoh, N. & Janbi, F. Quality of life assessment in Egyptian rheumatoid arthritis patients: Relation to clinical features and disease activity. The Egyptian Rheumatologist 38, 65–70, https://doi.org/10.1016/j.ejr.2015.04.002 (2016).
3. Li, Z. et al. Long non-coding RNAs in rheumatoid arthritis. Cell proliferation 51, https://doi.org/10.1111/cpr.12404 (2018).
4. Helmy, H. S. et al. Therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental models of rheumatoid arthritis. International journal of nanomedicine 12, 7015–7023, https://doi.org/10.2147/ijn.s147738 (2017).
5. Macedo, A. C. L. & Isaac, L. Systemic Lupus Erythematosus and Deficiencies of Early Components of the Complement Classical Pathway. Frontiers in Immunology 7, 55, https://doi.org/10.3389/fimmu.2016.00055 (2016).
Acknowledgements
The authors thank RA and SLE patients and all subjects who participated in this study. This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Author Contributions
M.S., H.H. and N.F. Conceived and designed the experiments. M.S., H.H., N.F. and O.S. Contributed the reagents and performed the experiments. M.S., H.H. and N.F. Analyzed the data and wrote the manuscript. O.S. and G.A. Collected the samples and contributed analysis tools.

Additional Information
Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019